D&A at other companies
Other financials
Where this comes from
Reported directly by AbCellera Biologics Inc. in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: AbCellera Biologics Inc.’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbCellera Biologics Inc.'s d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbCellera Biologics Inc.'s D&A?
- AbCellera Biologics Inc. (ABCL) reported D&A of $6.84M in Q1 2026.
- How has AbCellera Biologics Inc.'s D&A changed year-over-year?
- AbCellera Biologics Inc.'s D&A increased by 28.3% year-over-year, from $5.33M to $6.84M.
- What is the long-term trend for AbCellera Biologics Inc.'s D&A?
- Over 2 years (2021 to 2023), AbCellera Biologics Inc.'s D&A has grown at a 29.9% compound annual growth rate (CAGR), from $14.45M to $24.4M.
- What does D&A mean?
- Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.